Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial

References

• Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, et al. 2006. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry 67(8):1253–1260.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. 2008. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2):101–107.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiménez M, Martínez-García O, Pérez-Iglesias R, Ramírez ML, Vázquez-Barquero JL, Crespo-Facorro B. 2010. Prevention of antipsychotic-induced weight gain with early behavioral intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res 116(1):16–9.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. 2005. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005;5:3.
   PubMed Web of Science ®Google Scholar
• Chen CK, Chen YC, Huang YS. 2009. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin Neurosci 63(1):17–22.
   PubMed Web of Science ®Google Scholar
• Cordes J, Sinha-Röder A, Kahl KG, Malevani J, Thuenker J, Lange-Asschenfeldt C, et al. 2008. Therapeutic options for weight management in schizophrenic patients treated with atypi cal antipsychotics. Fortschr Neurol Psychiatr 76(12): 703–714.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. 2009. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 302(16):1765–1773; erratum: 302(21):2322.
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft für Ernährung eV. 2006. Evidenzbasierte Leitlinie: Fettkonsum und Prävention ausgewählter durch Ernährung mitbedingter Krankheiten. Bonn (http://www.dge.de/leitlinie/).
   Google Scholar
• Drieling T, Biedermann NC, Scharer LO, Strobl N, Langosch JM. 2007. Psychotropic drug-induced change of weight: a review. Fortschr Neurol Psychiatr 75(2):65–80.
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. 2005. Nutritional intervention to prevent weight gain in patients commenced on olancapine: a randomised controlled trial. Aust NZ J Psychiatry 39:479–486.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. 2007. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 24(1): CD005148.
   Google Scholar
• Feeney L, Dempsey J, Moynihan F, Barry S. 2003. Changes in body mass indices of patients with schizophrenia 3 years following the introduction of a weight management programme. Ir Med J 96(9):276–277.
   PubMedGoogle Scholar
• Fenton WS, Chavez MR. 2006. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 163(10):697–704.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. 2008. Comorbid somatic illnesses in patients with severe mental disorders: clini cal, policy, and research challenges. J Clin Psychiatry 69(4):514–519.
   PubMed Web of Science ®Google Scholar
• Gaur N, Grover S. 2010. Factors associated with weight gain with olanzapine. World J Biol Psychiatry 11(2):156–157.
   PubMed Web of Science ®Google Scholar
• Guy W. 1976. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health. 218–222.
   Google Scholar
• Haddad P. 2005. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19(6 Suppl): 16–27.
   PubMedGoogle Scholar
• Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. 2005. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62(1):19–28.
   PubMed Web of Science ®Google Scholar
• Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. 2007. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32(2): 289–297.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. 2008. Olanzapine: review of safety. Expert Opin Drug Saf 7(6):761–769.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261 76.
   Web of Science ®Google Scholar
• Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. 2005. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25(3):255–258.
   PubMed Web of Science ®Google Scholar
• Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, et al. 2010. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 11(2 Pt 2):262–267.
   PubMed Web of Science ®Google Scholar
• Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, et al. 2006. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 67(4): 547–553.
   PubMed Web of Science ®Google Scholar
• Lachin JM. 1988. Statistical properties of randomization in clinical trials. Control Clin Trials 9(4):289–311.
   PubMedGoogle Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62(4): 361–370.
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. 2003. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 35(3):237–241.
   PubMed Web of Science ®Google Scholar
• McElroy SL. 2009. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry 70(Suppl 3):12–21.
   PubMedGoogle Scholar
• McIntyre RS. 2009. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 70(6):e17.
   Google Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65(4):471–477.
   PubMed Web of Science ®Google Scholar
• Michaelis D, Rjasanowski I, Hildmann W, Kohnert KD, Richter KV. 1985. Validity of WHO criteria for classification of newly diagnosed diabetics. Exp Clin Endocrinol 85(1):61–9.
   PubMedGoogle Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S7–14.
   Google Scholar
• Newcomer JW. 2007. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl 4):8–13.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59(4):337–345.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. 2009. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 70(4):487–499.
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparén P. 2000. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45(1–2):21–28.
   PubMed Web of Science ®Google Scholar
• Pajonk FG, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I, et al. 2010. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 67(2):133–143.
   PubMed Web of Science ®Google Scholar
• Pendlebury J, Haddad P, Dursun S. 2005. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 20(6): 447–448.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33.
   PubMed Web of Science ®Google Scholar
• Simon V, van Winkel R, De Hert M. 2009. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70(7): 1041–1050.
   PubMed Web of Science ®Google Scholar
• Smith M, Porter R. 2009. Antipsychotics and risk of diabetes in schizophrenia. Br J Psychiatry 194(2):186–187.
   PubMed Web of Science ®Google Scholar
• Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. 2007. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 24(5):481–485.
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. 2003. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28(Suppl 1):9–26.
   PubMed Web of Science ®Google Scholar
• Thakore JH. 2005. Metabolic syndrome and schizophrenia. Br J Psychiatry 186:455–456.
   PubMed Web of Science ®Google Scholar
• Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, et al. 2009. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 10(4 Pt 3):729–740.
   PubMed Web of Science ®Google Scholar
• Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. 2003. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 54(8): 1155–1157.
   PubMed Web of Science ®Google Scholar
• Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. 2007. Outcomes of obese, clozapine-treated inpatients with schizophrenia plaxed on a six-month diet and physical activity program. Psychiatr Serv 58:544–550 (previous presentation at the 2nd European Conference on Schizophrenia Research, 21—23 September 2009, Berlin, Germany.
   PubMed Web of Science ®Google Scholar